Shares of Fate Therapeutics /zigman2/quotes/209623007/composite FATE +1.45% gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in a very small Phase 1 trial as treatments for acute myeloid leukemia and as a combination therapy for advanced B-cell lymphoma. Separately, Fate said preclinical data for FT596 was also positive, and it will begin enrolling patients in its first human trial early next year. Fate's stock is up 46% year-to-date. The S&P /zigman2/quotes/210599714/realtime SPX +0.83% has gained 25% during the same timeframe.